about
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysisTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disabilityThe Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.Eliminating encephalitogenic T cells without undermining protective immunityDisease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study.The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity-Report of a Case and Review of the Literature.Autologous haematopoietic stem cell transplantation for neurological diseases.How far away from having an effective treatment option for progressive multiple sclerosis are we?Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.Inhibiting repulsive guidance molecule-a suppresses secondary progression in mouse models of multiple sclerosis
P2860
Q24185820-7B44E513-7F9C-4851-A200-0E8F499F8871Q26798434-7305A395-CC65-4DD3-911C-8F01674A9AE7Q33755345-B8B132FA-D01B-4975-8D38-D581C156E5C5Q35866381-E7C8E1E5-7262-4CEA-B65A-9D29F4305F6BQ36062456-FFFFB783-9116-4D2E-953C-CBC89139476EQ36353053-7E6F4828-6B28-4FE0-8974-AED97F35B381Q36982030-721D7591-13BB-402B-99C7-D05C6E77FC01Q37412980-BF7ED6BF-53CB-4C77-86EE-94E93C9D9EDFQ38137114-CE171D86-E6B6-4653-B4A6-560F3F1C914DQ38960854-7CBC5253-03D0-4DD7-9DD4-76D697A799C0Q41318551-F3EB506F-F710-4C69-820D-F498BD2AAD8CQ45066717-E33D52C9-B601-43C1-A165-3A4FD850964EQ47106449-1C4D9073-3D30-4867-83E0-7B4EFB1D135AQ48136043-57C950EE-235F-4A1C-8C4C-EE7FB66784F8Q48179465-7861003E-9CE4-4352-8A53-192F6E5532A7Q48607199-046A1D1A-1572-4B2F-AEDE-B5B4D8288C63Q58605699-F009A7DB-B253-4EB1-B8FA-689A6F8448FE
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Mitoxantrone for multiple sclerosis
@ast
Mitoxantrone for multiple sclerosis
@en
Mitoxantrone for multiple sclerosis
@en-gb
Mitoxantrone for multiple sclerosis
@nl
type
label
Mitoxantrone for multiple sclerosis
@ast
Mitoxantrone for multiple sclerosis
@en
Mitoxantrone for multiple sclerosis
@en-gb
Mitoxantrone for multiple sclerosis
@nl
prefLabel
Mitoxantrone for multiple sclerosis
@ast
Mitoxantrone for multiple sclerosis
@en
Mitoxantrone for multiple sclerosis
@en-gb
Mitoxantrone for multiple sclerosis
@nl
P2860
P50
P3181
P1476
Mitoxantrone for multiple sclerosis
@en
P2093
Giancarlo Comi
Ruggero Capra
P2860
P304
P3181
P356
10.1002/14651858.CD002127.PUB3
P407
P577
2013-05-31T00:00:00Z